This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners & Losers

The small-cap sector largely managed to stay afloat Thursday amid surging names like Acme Packet (APKT).

The Burlington, Mass., company racked up 22.6% gains on second-quarter non-GAAP income of $5.7 million, or 9 cents a share. That tops the average analysts' estimate by a penny, according to Thomson Financial. Shares were up $2.35 to $12.77.

San Diego's Cubic (CUB - Get Report), which makes defense electronics and transportation-fare-collection systems, bounced 19.4% to $32.70 on a decisive earnings beat. Fiscal third-quarter earnings rose sharply to $11.2 million, or 42 cents a share, from 22 cents a share a year ago. Analysts were looking for 33 cents a share.

Both Acme and Cubic helped to prop up the Russell 2000, which was lately climbing 1.7 points, or 0.2%, to 779.62. The S&P SmallCap 600 added 0.4% to 412.53.

Elsewhere, BluePhoenix Solutions (BPHX) rode high after the Israel-based business-software company inked a letter of intent to buy Texas-based Amalgamated Software North America. The deal is worth $9.5 million in cash, in addition to an earn-out for ASNA shareholders contingent on achievement of certain profit targets. BluePhoenix shares jumped $1.76, or 15.6%, to $13.06.

Pozen (POZN - Get Report) shares took a 43% free fall, however, after the Food and Drug Administration said it and partner GlaxoSmithKline (GSK) need to collect more safety data on their proposed migraine drug Trexima. North Carolina-based Pozen lost $7.50 to $9.95; Glaxo ticked up 0.7% to $51.97.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BPHX $2.67 -1.48%
CUB $47.92 0.07%
LQDT $9.91 -2.00%
POZN $6.48 -1.10%
AAPL $130.81 -0.74%

Markets

DOW 18,038.84 -87.28 -0.48%
S&P 500 2,107.53 -13.26 -0.63%
NASDAQ 5,068.2610 -29.7150 -0.58%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs